Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clinical management of women at increased risk for breast cancer

Summary

A large number of women in the population are at risk for the development of breast cancer. Methods now exist to accurately assess risk and to provide quantitative estimates of the chance of a woman developing breast cancer in her lifetime. Histologic assessment of premalignant breast pathology aids in the evaluation of risk. The availability of primary chemoprevention clinical trials reduces the number of indications for prophylactic mastectomy. Women at risk for breast cancer and women who have had a malignant lesion at another anatomic site have an increased risk for new cancers at multiple sites. We propose screening strategies based on epidemiologic information about the risks of these diseases and on the predictive value of the available screening tests. The merits and inadequacies of specific management strategies are considered. We review the risks and benefits of estrogen replacement therapy for women at increased risk for breast cancer and consider the ethical implications of both risk assessment and the various interventions.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Anderson DE, Badzioch MD: Risk of familial cancer. Cancer 56:383–387, 1985

  2. 2.

    Lynch HT, Albano WA, Heieck JJ, Mulcahy GM, Lynch JF, Layton MA, Danes BS: Genetics, biomarkers, and control of breast cancer: A review. Cancer Genet Cytogenet 13:43–92, 1984

  3. 3.

    Lynch HT, Conway T, Watson P, Schreiman J, Fitzgibbons RJ Jr: Extremely early onset hereditary breast cancer (HBC): Surveillance/management implications. Nebr Med J 73:97–100, 1988

  4. 4.

    Lynch HT, Lynch JF: Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet 23:369–372, 1986

  5. 5.

    Love RR: Genetics and human cancer: Family history and common cancers. Wisc Med J 86:20–21, 1987

  6. 6.

    Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL: Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 269:1970–1974, 1993.

  7. 7.

    Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886, 1989

  8. 8.

    Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151, 1985

  9. 9.

    McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D: Histologic types of benign breast disease and the risk for breast cancer. Cancer 69:1408–1414, 1992

  10. 10.

    London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941–944, 1992.

  11. 11.

    Vogel VG: High-risk populations as targets for breast cancer prevention trials. Prev Med 20:86–100, 1991

  12. 12.

    Hislop TG, Elwood JM: Risk factors for benign breast disease: A 30-year cohort study. Can Med Assoc J 124:283–291, 1981

  13. 13.

    Page DL, Japaze H: Noninfiltrating (in situ) carcinoma.In: Bland KI, Copeland EM III (eds) The Breast — Comprehensive Management of Benign and Malignant Diseases. WB Saunders Co, Philadelphia, 1991, pp 169–192

  14. 14.

    Beute BJ, Kalisher L, Hutter RVP: Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. Am J Roentgenol 157:257–265, 1991.

  15. 15.

    Temple WJ, Jenkins M, Alexander F, Hwang WS, Marx LH, Lees AW, Williams HT, Pambrun MG: Natural history ofin situ breast cancer in a defined population. Ann Surg 210:653–657, 1989

  16. 16.

    Claus EB, Risch N, Thompson WD, Carter D: Relationship between breast histopathology and family history of breast cancer. Cancer 71:147–153, 1993.

  17. 17.

    Frykberg ER, Ames FC, Bland KI: Current concepts for management of early (in situ and occult invasive) breast carcinoma.In: Bland KI, Copeland EM III(eds) The Breast — Comprehensive Management of Benign and Malignant Diseases. WB Saunders Co, Philadelphia, 1991, pp 731–751

  18. 18.

    Solin LJ, Recht A, Fourquet A, Kurtz J, Kuske R, McNeese M, McCormick B, Cross MA, Schultz DJ, Bornstein BA: Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 68:2337–2334, 1991

  19. 19.

    Wolfe JN: Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 126:1130–1139, 1976

  20. 20.

    Brisson J, Morrison AS, Kopans DB, Sadowsky NL, Kalisher L, Twaddle JA, Meyer JE, Henschke CI, Cole P: Height and weight, mammographic features of breast tissue and breast cancer risk. Am J Epidemiol 119:371–381, 1984

  21. 21.

    Carlile T, Kopecky KJ, Thompson DJ, Whitehead JR, Gilbert FI, Present AJ, Threatt BA, Krook P, Hadaway E: Breast cancer prediction and the Wolfe classification of mammograms. JAMA 254:1050–1053, 1985

  22. 22.

    Bergkvist L, Tabar L, Bergstrom R, Adami H-O: Epidemiologic determinants of the mammographic parenchymal pattern: A population-based study within a mammographic screening program. Am J Epidemiol 126:1075–1081, 1987

  23. 23.

    Brisson J, Morrison AS, Khalid N: Mammographic parenchymal features and breast cancer in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 80:1534–1540, 1988

  24. 24.

    Saftlas AF, Wolfe JN, Hoover RN, Brinton LA, Schairer C, Salane M, Szklo M: Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol 129:518–526, 1989

  25. 25.

    Skolnick MH, Cannon-Albright LA, Goldgar DE, Ward JH, Marshall CJ, Schumann GB, Hogle H, McWhorter WP, Wright EC, Tran TD: Inheritance of proliferative breast disease in breast cancer kindreds. Science 250:1715–1720, 1990

  26. 26.

    Ward JH, Marshall CJ, Schumann GB, Hogle H, Cannon-Albright LA, McWhorter WP, Eyre HJ, Skolnick MH: Detection of proliferative breast disease by fourquadrant, fine-needle aspiration. J Natl Cancer Inst 82:964–966, 1990

  27. 27.

    Fabian C, Kamel S, McKittrich R, Zalles C, Chin T, Kimler B: Prevalence of abnormal biomarkers in fine needle aspirates in a high risk population: potential for use in risk prediction. Proc Am Assoc Cancer Res 34:A1556, 1993

  28. 28.

    Kelsey JL, Berkowitz GS: Breast cancer epidemiology. Cancer Res 48:5615–5623, 1988

  29. 29.

    Kelsey JL, Gammon MD: Epidemiology of breast cancer. Epidemiol Rev 12:228–240, 1990

  30. 30.

    Kelsey JL, Gammon MD, John EM: Reproductive factors and breast cancer. Epidemiol Rev 15:36–47, 1993

  31. 31.

    Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE: Moderate alcohol consumption and the risk of breast cancer. N Engl J Med 316:1174–1180, 1987

  32. 32.

    Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131:961–972, 1990

  33. 33.

    Claus EB, Risch N, Thompson WD: The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat (in press)

  34. 34.

    Lynch HT, Watson P, Bewtra C, Conway TA, Hippee CR, Kaur P, Lynch JF, Ponder BA: Hereditary ovarian cancer: Heterogeneity in age at diagnosis. Cancer 67:1460–1466, 1991

  35. 35.

    Muller H, Weber W, Kuttapa T: Familial Cancer. Karger, New York, 1985

  36. 36.

    Donovan AJ: Bilateral breast carcinoma.In: Bland KI, Copeland EM III (eds) The Breast — Comprehensive Management of Benign and Malignant Disease. WB Saunders Co, Philadelphia, 1991, pp 1021–1029

  37. 37.

    Lynch HT, Krush AJ, Guirgis H: Genetic factors in families with combined gastrointestinal and breast cancer. Am J Gastroenterol 1:31–40, 1973

  38. 38.

    Lynch HT, Albano WA, Lynch JF, Ruma TA: Recognition of the cancer family syndrome. Gastroenterol 84:672–673, 1983

  39. 39.

    Mettlin C: Breast cancer risk factors — contributions to planning breast cancer control. Cancer 69:1904–1910, 1992

  40. 40.

    Vogel VG: Screening younger women at risk for breast cancer. J Natl Cancer Inst Monographs (in press).

  41. 41.

    Meyer JE, Kopans DB, Oot R: Breast cancer visualized by mammography in patients under 35. Radiology 147:93–94, 1983

  42. 42.

    Love SM: Use of risk factors in counseling patients. Hematol/Oncol Clin North Am 3:599–610, 1989

  43. 43.

    Bland KI, O'Neal B, Weiner LJ, Tobin GR: Onestage simple mastectomy with immediate reconstruction for high-risk patients. Arch Surg 121:221–225, 1986

  44. 44.

    Goodnight JE, Quagliana JM, Morton DL: Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 26:198–201, 1984

  45. 45.

    Pennisi VR, Capozzi A: Subcutaneous mastectomy data: A final statistical analysis of 1500 patients. Aesthetic Plast Surg 13:15–21, 1989.

  46. 46.

    Rubin LR: Prophylactic mastectomy with immediate reconstruction for the high-risk woman. Clinics in Plastic Surgery 11:369–381, 1984

  47. 47.

    Ziegler LD, Kroll SS: Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14:451–454, 1991

  48. 48.

    Fisher JC: The silicone controversy — when will science prevail? N Engl J Med 326:1696–1698, 1992

  49. 49.

    Kline TS, Kline IK: Breast — guides to clinical aspiration biopsy. Igaku-Shoin, New York, 1989, pp 1–39

  50. 50.

    Wapnir IL, Rabinowitz B, Greco RS: A reappraisal of prophylactic mastectomy. Surg Gynecol Obstet 171:171–184, 1990

  51. 51.

    Early Breast Cancer Trialists' Collaborative Group: Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15, 1992

  52. 52.

    Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82:18–21, 1990

  53. 53.

    Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, De Mets DL: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860–864, 1991

  54. 54.

    Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, De Mets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856, 1992

  55. 55.

    Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar M-L: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet i:117–119, 1989

  56. 56.

    Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450–1459, 1991

  57. 57.

    Huka BS: Hormone-replacement therapy and the risk of breast cancer. CA — Cancer J Clin 40:289–296, 1990

  58. 58.

    Gambrell RD Jr, Maier RC, Sanders BI: Decreased incidence of breast cancer in postmenopausal estrogenprogestogen users. Obstet Gynecol 62:435–443, 1983

  59. 59.

    Brinton LA, Hoover R, Fraumeni JF Jr: Menopausal estrogens and breast cancer risk: an expanded casecontrol study. Br J Cancer 54:825–32, 1986

  60. 60.

    McDonald JA, Weiss NS, Daling JR, Francis AM, Polissar L: Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 7:193–9, 1986

  61. 61.

    Bergkvist L, Adami H-O, Person I, Hoover R, Schairer C: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321:293–297, 1989

  62. 62.

    Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S: Estrogen replacement therapy and the risk of breast cancer: Results from the case-control surveillance study. Am J Epidemiol 134:1386–1395, 1991

  63. 63.

    Dupont WD, Page DL, Rogers LW, Parl FF: Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 63:948–957, 1989

  64. 64.

    Mills PK, Beeson WL, Phillips RL, Fraser GE: Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 64:591–597, 1987

  65. 65.

    Hunt K, Vessey M: Long-term effects of postmenopausal hormone therapy. Br J Hosp Med 38:450–543, 456–460, 1987

  66. 66.

    Barrett-Connor E: Postmenopausal estrogen replacement and breast cancer. N Engl J Med 321:319–320, 1989

  67. 67.

    Lippman ME, Swain SM: Endocrine-responsive cancers of humans.In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology (ed 8). WB Saunders Co, Philadelphia, 1992, pp 1577–1597

  68. 68.

    Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zach MM, Flanders WD, Berkelman RL: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985–1990, 1991

  69. 69.

    Armstrong BK: Oestrogen therapy after the menopause — boon or bane? Med J Aus 148:213–214, 1988

  70. 70.

    DuPont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67–72, 1991

  71. 71.

    Danforth DN: How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology 5:23–30, 1991

  72. 72.

    Schlesselman JJ, Stadel BV, Murray P, Lai S: Breast cancer in relation to early use of oral contraceptives -no evidence of a latent effect. JAMA 259:1828–1833, 1988

  73. 73.

    Lipnick RJ, Buring JE, Hennekens CH, Rosner B, Willett W, Bain C, Stampfer MJ, Colditz GA, Peto R, Speizer FE: Oral contraceptives and breast cancer — a prospective cohort study. JAMA 255:58–61, 1986

  74. 74.

    Sattin RW, Rubin GL, Wingo PA, Webster LA, Ory HW: Oral-contraceptive use and the risk of breast cancer. N Engl J Med 315:405–411, 1986

  75. 75.

    The Centers for Disease Control Cancer and Steroid Hormone Study: Long-term oral contraceptive use and the risk of breast cancer. JAMA 249:1591–1595, 1983

  76. 76.

    Carr BR: Disorders of the ovary and female reproductive tract.In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology (ed 8). WB Saunders Co, Philadelphia, 1992, pp 733–798

  77. 77.

    Barrett-Connor E, Bush TJ: Estrogen and coronary heart disease in women. JAMA 265:1861–1867, 1991

  78. 78.

    Paganini-Hill A, Ross RK, Henderson BE: Postmenopausal oestrogen treatment and stroke: A prospective study. Br Med J 297:519–522, 1988

  79. 79.

    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016–1037, 1992

  80. 80.

    Ettinger B, Genant HK, Conn CE: Postmenopausal bone loss is prevented by treatment with low-dose estrogen with calcium. Ann Intern Med 106:40–45, 1987

  81. 81.

    Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA: Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 317:1169–1174, 1987

  82. 82.

    Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48:246–253, 1988

  83. 83.

    Bernstein L, Ross RK, Henderson BE: Prospects for the primary prevention of breast cancer. Am J Epidemiol 135:142–152, 1992

  84. 84.

    Warren MP, Brooks-Gunn J, Hamilton LH, Warren F, Hamilton WG: Scoliosis and fractures in young ballet dancers: Relation to delayed menarche and secondary amenorrhea. N Engl J Med 314:1348–1353, 1986

  85. 85.

    Spicer D, Pike MC, Henderson BE: The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology 4:49–54, 1990

  86. 86.

    Theriault RL, Sellin RV: A clinical dilemma: Estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Ann Oncol 2:709–717, 1991

  87. 87.

    King M-C, Rowell S, Love SM: Inherited breast and ovarian cancer. What are the risks? What are the choices? JAMA 269:1975–1980, 1993

  88. 88.

    American College of Physicians: Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 117:1038–1041, 1992

  89. 89.

    Lerman C, Rimer BK, Engstrom PF: Cancer risk notification: Psychosocial and ethical implications. J Clin Oncol 9:1275–1282, 1991

  90. 90.

    Vogel VG, Graves DS, Vernon SW, Lord JA, Winn RJ, Peters GN: Mammographic screening of women with increased risk of breast cancer. Cancer 66:1613–1620, 1990

  91. 91.

    Bondy ML, Vogel VG, Halabi S, Lustbader ED: Identification of women at increased risk for breast cancer in a population-based screening program. Cancer Epidemiol Biomark Prevent 1:143–147, 1992

  92. 92.

    Newell GR, Vogel VG: Personal risk factors — What do they mean? Cancer 62:1695–1701, 1988

  93. 93.

    Vogel VG, Graves DS, Coody DK, Winn RJ, Peters GN: Breast screening compliance following a statewide low-cost mammography project. Cancer Detect Prevent 14:573–576, 1990

  94. 94.

    Schatzkin A, Greenwald P, Byar DP, Clifford CK: The dietary fat-breast cancer hypothesis is alive. JAMA 261:3284–3287, 1989

  95. 95.

    Miller AB, Kelly A, Choi NW, Matthews V, Morgan RW, Munan L, Burch JD, Feather J, Howe GR, Jain M: A study of diet and breast cancer. Am J Epidemiol 107:499–509, 1978

  96. 96.

    Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE: Dietary fat and the risk of breast cancer. N Engl J Med 316:22–28, 1987

  97. 97.

    Willett WC, Hunter DJ, Stampfer MJ, Colditz G, Manson JE, Spiegelman D, Rosner B, Hennekens CH, Speizer FE: Dietary fat and fiber in relation to risk of breast cancer. An 8-year follow-up. JAMA 268:2037–2044, 1992

  98. 98.

    Hunter DJ, Manson JE, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE, Willett WC: A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 329:234–240, 1993

  99. 99.

    Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths T, Parker L, Zurawski VR, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887, 1983

  100. 100.

    Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J, Oram D: Multimodal approach to screening for ovarian cancer. Lancet i:268–271, 1988

  101. 101.

    Van Nagell JR Jr: Ovarian cancer screening. Cancer 68:679–680, 1991

  102. 102.

    Einhorn N, Knapp RC, Bast RC, Zurawski VR Jr: CA125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant disease of the ovary. Acta Oncol 28:655–657, 1989

  103. 103.

    MacKay EV, Khoo SK, Daunter B: Tumor markers.In: Coppleson M (ed) Gynecologic Oncology (ed 2). Churchill Livingston, Edinburgh, 1992, pp 405–415

  104. 104.

    Bourne TH, Whitehead MI, Campbell S, Royston P, Bhan V, Collins WP: Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43:92–97, 1991

  105. 105.

    Rosen P, Fireman Z, Figer A, Ron E: Colorectal tumor screening in women with a past history of breast, uterine, and ovarian malignancies. Cancer 57:1235–1239, 1986

  106. 106.

    Eddy DM: Screening for colorectal cancer. Ann Intern Med 113:373–384, 1990

  107. 107.

    Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328:1365–1371, 1993

  108. 108.

    Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM: Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84:1572–1575, 1992

  109. 109.

    MacMahon B, Austin JH: Associations of carcinomas of the breast and corpus uteri. Cancer 23:275–280, 1969

  110. 110.

    Fornander T, Rutqvist LE, Wilking N: Effects of tamoxifen on the female genital tract. Ann NY Acad Sci 622:469–476, 1991

  111. 111.

    Kaunitz AM, Masciello A, Ostrowski M, Rovira EZ: Comparison of endometrial biopsy with endometrial Bipelle and Vabra aspirator. J Reprod Med 33:427–431, 1988

  112. 112.

    Henig I, Chan P, Tredway DR, Maw GM, Gullett AJ, Cheatwood M: Evaluation of the Pipelle currette for endometrial biopsy. J Reprod Med 34:786–789, 1989

  113. 113.

    Vogel VG, Shepherd B, Craig K, Winn RJ, Bolleter LR, Coody DK: A randomized CCOP trial to improve mammographic screening compliance among women with family histories of breast cancer: Trial design and preliminary results. Prev Med 19:599–600, 1990

  114. 114.

    Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49–53, 1991

Download references

Author information

Correspondence to Victor G. Vogel.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vogel, V.G., Yeomans, A. & Higginbotham, E. Clinical management of women at increased risk for breast cancer. Breast Cancer Res Tr 28, 195–210 (1993). https://doi.org/10.1007/BF00666431

Download citation

Key words

  • breast neoplasms
  • genetics
  • prevention
  • risk factors
  • screening